The loan amendment buys time but at the cost of massive potential dilution. The $1.00 conversion/warrant price is likely below the current market price (given the $13M market cap and ~$10M debt), creating a strong overhang. Monitor for any monthly put option exercises by the company, which would signal immediate dilution. The 4.99% blocker prevents Avenue from exceeding that threshold, but the overhang remains until the loan is repaid or converted. The stock is likely to trade under pressure from the dilutive structure.
Price Chart
Executive Summary
CalciMedica amended its existing loan agreement with Avenue Venture Opportunities Fund II, extending the interest-only period to September 2027 and the maturity date to September 2029, while increasing the final payment fee by $200,000. The lender's conversion right was expanded from $1M to $3M of principal, and the company received a put option to force conversion under certain conditions. Additionally, the existing warrant exercise price was reduced from $2.32 to $1.00, and a new warrant for 1,000,000 shares at $1.00 was issued to the lender, both subject to a 4.99% beneficial ownership limitation. This restructuring provides near-term liquidity relief but introduces significant future dilution risk via the expanded conversion option and new warrants.
Key Financial Metrics
Key Facts
- Aggregate principal outstanding under the loan agreement is $10,000,000.
- Interest-only period extended from September 30, 2026 to September 30, 2027; maturity extended from September 1, 2028 to September 1, 2029.
- Final payment fee increased by $200,000.
- Lender's conversion right expanded from $1,000,000 to $3,000,000 of principal, convertible at $1.00 per share (or via pre-funded warrants at $0.9999 per share).
- Company granted a put option to force conversion monthly, capped at 20% of 15-day average daily volume, exercisable only if VWAP is 50% above the conversion price.
- Existing warrant (641,163 shares) exercise price reduced from $2.32 to $1.00.
- New warrant issued for 1,000,000 shares at $1.00 per share, exercisable until June 23, 2031.
- All conversion and warrant exercises subject to a 4.99% beneficial ownership limitation (can be increased to 19.99% with 61 days' notice).
- Market cap is approximately $13M, making potential dilution from $3M conversion and 1.64M warrants highly material.
Financial Impact
Up to $3M of the $10M loan principal can be converted into common stock at $1.00/share, plus 1,641,163 total warrant shares exercisable at $1.00/share. At a ~$13M market cap, full conversion and warrant exercise could add ~3M+ shares, representing potentially >50% dilution.
Risk Factors
- Massive dilution risk: up to $3M principal conversion + 1.64M warrants at $1.00/share could increase share count by 50%+ relative to current float.
- Put option allows company to force conversion monthly, creating a steady dilutive overhang.
- Low market cap ($13M) relative to debt ($10M) suggests equity is deeply distressed; the loan restructuring may signal inability to repay.
- Warrant exercise price ($1.00) may be above market, limiting immediate cash exercise but cashless exercise still dilutes.
- Beneficial ownership limitation can be increased to 19.99%, allowing Avenue to accumulate a large stake.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-280223 |
| Document: d40651dex41.htm | 0001193125-26-280223 |
| Document: d40651d8k.htm | 0001193125-26-280223 |
| Document: d40651dex101.htm | 0001193125-26-280223 |
| Document: d40651dex42.htm | 0001193125-26-280223 |
| Document: 0001193125-26-280223-index-headers.html | 0001193125-26-280223 |
| Document: 0001193125-26-280223-index.html | 0001193125-26-280223 |
| Document: 0001193125-26-280223.txt | 0001193125-26-280223 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.02 | awaiting T+20 | — | $1.30 (−27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 30, 2026 26d ago | 424B5 | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 2, 2026 7w ago | 8-K | $2.10 $1.65 | ▲ +21.43% | ▲ +21.28% | $1.30 (+38.10%) |
Aug 11, 2026 10w ago | 8-K | $0.6577 $0.4590 | ▲ +30.21% | ▲ +29.15% | $1.30 (−97.66%) |
Aug 11, 2026 10w ago | Press Release | $0.6577 $0.4590 | ▼ −30.21% | ▼ −29.15% | $1.30 (+97.66%) |
Jul 10, 2026 15w ago | 3 | $0.8178 $0.6590 | ▼ −19.42% | ▼ −22.60% | $1.30 (+58.96%) |
Jun 24, 2026 17w ago | 8-K | $0.5973 $0.7159 | ▼ −19.86% | ▼ −19.18% | $1.30 (−117.65%) |
May 12, 2026 23w ago | 8-K | $0.6300 $0.9320 | ▲ +47.94% | ▲ +49.66% | $1.30 (+106.35%) |
Mar 12, 2026 32w ago | EFFECT | $0.7260 $0.6180 | ▼ −14.88% | ▼ −16.85% | $1.30 (+79.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers